Boston Family Office LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 21.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 111,675 shares of the pharmacy operator’s stock after buying an additional 19,435 shares during the period. CVS Health Corporation makes up 1.1% of Boston Family Office LLC’s holdings, making the stock its 29th largest position. Boston Family Office LLC’s holdings in CVS Health Corporation were worth $8,766,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Mercer Capital Advisers Inc. bought a new stake in CVS Health Corporation during the first quarter valued at $118,000. Sowell Financial Services LLC acquired a new position in shares of CVS Health Corporation during the fourth quarter worth approximately $140,000. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of CVS Health Corporation during the fourth quarter worth approximately $156,000. Orrstown Financial Services Inc. boosted its position in shares of CVS Health Corporation by 2,000.0% in the first quarter. Orrstown Financial Services Inc. now owns 2,100 shares of the pharmacy operator’s stock worth $165,000 after buying an additional 2,000 shares in the last quarter. Finally, Edmp Inc. purchased a new stake in CVS Health Corporation during the first quarter valued at $202,000. Institutional investors and hedge funds own 82.31% of the company’s stock.
CVS Health Corporation (CVS) traded down 1.56% during midday trading on Friday, hitting $77.66. 5,005,371 shares of the stock traded hands. CVS Health Corporation has a 52 week low of $69.30 and a 52 week high of $98.44. The stock’s 50-day moving average price is $78.68 and its 200 day moving average price is $78.94. The company has a market capitalization of $78.95 billion, a price-to-earnings ratio of 15.47 and a beta of 0.91.
CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.02. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The business had revenue of $45.69 billion during the quarter, compared to analyst estimates of $45.36 billion. During the same period last year, the firm posted $1.32 EPS. The company’s revenue was up 4.5% on a year-over-year basis. On average, equities research analysts predict that CVS Health Corporation will post $5.88 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 3rd. Shareholders of record on Monday, July 24th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date was Thursday, July 20th. CVS Health Corporation’s dividend payout ratio (DPR) is currently 39.92%.
WARNING: This story was originally posted by BNB Daily and is the property of of BNB Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/cvs-health-corporation-cvs-shares-bought-by-boston-family-office-llc-updated-updated.html.
A number of analysts recently weighed in on the stock. Vetr lowered shares of CVS Health Corporation from a “buy” rating to a “hold” rating and set a $85.78 price target for the company. in a report on Thursday, April 27th. Tigress Financial initiated coverage on shares of CVS Health Corporation in a research note on Thursday, April 27th. They issued a “buy” rating on the stock. Needham & Company LLC initiated coverage on shares of CVS Health Corporation in a research report on Tuesday, June 27th. They issued a “hold” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a research report on Monday, July 3rd. Finally, Leerink Swann set a $90.00 price objective on shares of CVS Health Corporation and gave the company a “buy” rating in a research report on Tuesday, June 27th. Nine analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $91.24.
In related news, EVP Helena Foulkes sold 20,333 shares of the firm’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $80.00, for a total value of $1,626,640.00. Following the completion of the sale, the executive vice president now directly owns 59,301 shares in the company, valued at $4,744,080. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard J. Swift sold 2,500 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total value of $199,050.00. Following the completion of the sale, the director now owns 3,258 shares of the company’s stock, valued at $259,401.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 273,675 shares of company stock valued at $21,831,647. Insiders own 0.61% of the company’s stock.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.